Ibane Abasolo Olaortua I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module. Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services LinkedIn Twitter Orcid Email Ibane Abasolo Olaortua LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.
I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB. Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease. I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).
Projects Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. IP: Ibane Abasolo Olaortua Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 116160 Reference: PI18/00871 Duration: 01/01/2019 - 30/06/2022 SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. IP: Ibane Abasolo Olaortua Collaborators: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats, Angels Alcina Mila, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 649580 Reference: SAFE-N-MEDTECHEC_H2020-NMBP2018 Duration: 01/04/2019 - 30/09/2023 (Nano) sistemes amb direccionament actiu per sensibilitzar cèl¿lules mare de càncer de còlon com a tractament antitumoral IP: Ibane Abasolo Olaortua Collaborators: Miriam Izquierdo Sans Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 67280.97 Reference: SLT006/17/00259 Duration: 01/03/2018 - 31/12/2020 Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease IP: - Collaborators: Ibane Abasolo Olaortua, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua Funding agency: EUROPEAN COMMISSION Funding: 266300.8 Reference: SMART4FABRY_H2020NMBP2016 Duration: 01/01/2017 - 31/12/2020 Pagination First page « Previous page ‹ … Page 3 Page 4 Current page 5 Page 6 Page 7 … Next page › Last page »
